Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT05092958
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
- NCT05092958 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built an HCP commentary report on NCT05092958 (avelumab and cabozantinib s-malate in Advanced Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05092958 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 37 | |
| YouTube | 6 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
- Interventions
- Avelumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (avelumab) · Active comparator
- Arm B (avelumab, cabozantinib) · Experimental
- Enrollment
- 654 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 3, 2022
- Primary completion
- Jul 15, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05092958 · updated Oct 26, 2026